From Liver Fat to Cancer: Perils of the Western Diet

被引:26
作者
Kim, Ju Youn [1 ,2 ]
He, Feng [3 ]
Karin, Michael [1 ,2 ]
机构
[1] Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, 9500 Gilman Dr, San Diego, CA 92093 USA
[2] Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Dept Pathol, 9500 Gilman Dr, San Diego, CA 92093 USA
[3] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China
关键词
obesity; cholesterol; NAFLD; NASH; HCC; ENDOPLASMIC-RETICULUM STRESS; DENSITY-LIPOPROTEIN-CHOLESTEROL; FARNESOID X RECEPTOR; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; TRANSCRIPTION FACTOR; METABOLIC SYNDROME; HEPATOCELLULAR-CARCINOMA; OBETICHOLIC ACID; CLINICAL-SIGNIFICANCE;
D O I
10.3390/cancers13051095
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-alcoholic steatohepatitis (NASH) is a common liver disease, characterized by fatty liver, chronic tissue damage, inflammation and fibrosis. NASH greatly increases the risk of the most common liver cancer, hepatocellular carcinoma (HCC), a leading cause of cancer related deaths worldwide. Here, we discuss how the Western Diet contributes to NASH and HCC development with a special emphasis on the roles of cholesterol and different metabolic regulators. Hepatocellular carcinoma (HCC), the most common type of primary liver cancer provides the prototypical example of an obesity-related cancer. The obesity epidemic gave rise to an enormous increase in the incidence of non-alcoholic fatty liver disease (NAFLD), a condition that affects one third of American adults. In about 20% of these individuals, simple liver steatosis (hepatosteatosis) progresses to non-alcoholic steatohepatitis (NASH) characterized by chronic liver injury, inflammation, and fibrosis. In addition to liver failure, NASH greatly increases the risk of HCC. Here we discuss the metabolic processes that control the progression from NAFLD to NASH and from NASH to HCC, with a special emphasis on the role of free-non-esterified cholesterol in the process.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 154 条
[1]   Dietary patterns and markers for the metabolic syndrome in Australian adolescents [J].
Ambrosini, G. L. ;
Huang, R. -C. ;
Mori, T. A. ;
Hands, B. P. ;
O'Sullivan, T. A. ;
de Klerk, N. H. ;
Beilin, L. J. ;
Oddy, W. H. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (04) :274-283
[2]   Recent insights on the role of cholesterol in non-alcoholic fatty liver disease [J].
Arguello, Graciela ;
Balboa, Elisa ;
Arrese, Marco ;
Zanlungo, Silvana .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2015, 1852 (09) :1765-1778
[3]   Role of FXR in Liver Inflammation During Nonalcoholic Steatohepatitis [J].
Armstrong L.E. ;
Guo G.L. .
Current Pharmacology Reports, 2017, 3 (2) :92-100
[4]   Obeticholic acid: expanding the therapeutic landscape of NASH [J].
Arrese, Marco ;
Cabrera, Daniel ;
Barrera, Francisco .
ANNALS OF HEPATOLOGY, 2015, 14 (03) :430-432
[5]   Fat Aussie -: A new Alstrom syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis [J].
Arsov, Todor ;
Silva, Diego G. ;
O'Bryan, Moira K. ;
Sainsbury, Amanda ;
Lee, Nicola J. ;
Kennedy, Claire ;
Manji, Shehnaaz S. M. ;
Nelms, Keats ;
Liu, Conan ;
Vinuesa, Carola G. ;
de Kretser, David M. .
MOLECULAR ENDOCRINOLOGY, 2006, 20 (07) :1610-1622
[6]   A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer [J].
Asgharpour, Amon ;
Cazanave, Sophie C. ;
Pacana, Tommy ;
Seneshaw, Mulugeta ;
Vincent, Robert ;
Banini, Bubu A. ;
Kumar, Divya Prasanna ;
Daita, Kalyani ;
Min, Hae-Ki ;
Mirshahi, Faridoddin ;
Bedossa, Pierre ;
Sun, Xiaochen ;
Hoshida, Yujin ;
Koduru, Srinivas V. ;
Contaifer, Daniel, Jr. ;
Warncke, Osinska ;
Wijesinghe, Dayanjan S. ;
Sanyal, Arun J. .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :579-588
[7]   miR-122-A key factor and therapeutic target in liver disease [J].
Bandiera, Simonetta ;
Pfeffer, Sebastien ;
Baumert, Thomas F. ;
Zeisel, Mirjam B. .
JOURNAL OF HEPATOLOGY, 2015, 62 (02) :448-457
[8]   Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study [J].
Bergman, Arthur ;
Carvajal-Gonzalez, Santos ;
Tarabar, Sanela ;
Saxena, Aditi R. ;
Esler, William R. ;
Amin, Neeta B. .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (04) :514-526
[9]   Internalization of Modified Lipids by CD36 and SR-A Leads to Hepatic Inflammation and Lysosomal Cholesterol Storage in Kupffer Cells [J].
Bieghs, Veerle ;
Verheyen, Fons ;
van Gorp, Patrick J. ;
Hendrikx, Tim ;
Wouters, Kristiaan ;
Luetjohann, Dieter ;
Gijbels, Marion J. J. ;
Febbraio, Maria ;
Binder, Christoph J. ;
Hofker, Marten H. ;
Shiri-Sverdlov, Ronit .
PLOS ONE, 2012, 7 (03)
[10]   LDL Receptor Knock-Out Mice Are a Physiological Model Particularly Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease [J].
Bieghs, Veerle ;
Van Gorp, Patrick J. ;
Wouters, Kristiaan ;
Hendrikx, Tim ;
Gijbels, Marion J. ;
van Bilsen, Marc ;
Bakker, Jaap ;
Binder, Christoph J. ;
Luetjohann, Dieter ;
Staels, Bart ;
Hofker, Marten H. ;
Shiri-Sverdlov, Ronit .
PLOS ONE, 2012, 7 (01)